Roche: With new diagnostics and revolutionary Brain-Shuttle agent towards the ultimate Alzheimer's breakthrough!
Reading Time: 4 minutes
The Swiss pharmaceutical giant Roche is currently undergoing an ambitious relaunch in the fiercely competitive Alzheimer diagnostics market, yet it faces significant skepticism from analysts. Since the summer of 2025, the company has offered a blood test aimed at reliably ruling out the neurological disease, but the market response has been lukewarm so far. Stefan Schneider, industry expert at the Swiss investment bank Vontobel, sums up the disappointment: "I simply haven't heard anything more about Roche's first Alzheimer test. Given that Roche...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
